Zobrazeno 1 - 10
of 60
pro vyhledávání: '"John J Talley"'
Autor:
Scott M. Ebert, Celine S. Nicolas, Paul Schreiber, Jaime G. Lopez, Alan T. Taylor, Andrew R. Judge, Sarah M. Judge, Blake B. Rasmussen, John J. Talley, Christophe A. Rème, Christopher M. Adams
Publikováno v:
Animals, Vol 14, Iss 2, p 186 (2024)
Muscle atrophy and weakness are prevalent and debilitating conditions in dogs that cannot be reliably prevented or treated by current approaches. In non-canine species, the natural dietary compound ursolic acid inhibits molecular mechanisms of muscle
Externí odkaz:
https://doaj.org/article/493b01afca24468aa78b04e49c41e4a3
Autor:
Scott M Ebert, Blake B Rasmussen, Andrew R Judge, Sarah M Judge, Lars Larsson, Ronald C Wek, Tracy G Anthony, George R Marcotte, Matthew J Miller, Mark A Yorek, Adrian Vella, Elena Volpi, Jennifer I Stern, Matthew D Strub, Zachary Ryan, John J Talley, Christopher M Adams
Publikováno v:
J Nutr
Activating transcription factor 4 (ATF4) is a multifunctional transcription regulatory protein in the basic leucine zipper superfamily. ATF4 can be expressed in most if not all mammalian cell types, and it can participate in a variety of cellular res
Publikováno v:
Mini-Reviews in Medicinal Chemistry. 16:1284-1289
Coxibs are a class of powerful drugs used by millions of people worldwide to treat a wide variety of ailments such as muscular skeletal pain and inflammation. The primary mechanism of action of coxibs is the potent inhibition of the COX-2 enzyme. Unf
Autor:
Steven A. Bullard, Daryl J. Murry, Daniel K. Fox, Jason M. Dierdorff, Christopher M. Adams, Kale S. Bongers, Michael C. Dyle, David K. Meyerholz, John J. Talley, Scott M. Ebert, Vitor A. Lira
Publikováno v:
The Journal of Biological Chemistry
Background: Aging reduces skeletal muscle strength and mass. Results: The transcription factor ATF4 is required for age-related muscle weakness and atrophy, and the small molecules ursolic acid and tomatidine reduce ATF4 activity, weakness, and atrop
Synthesis and Evaluation of Novel Erlotinib–NSAID Conjugates as More Comprehensive Anticancer Agents
Autor:
Micky D. Tortorella, Guan Jiantong, Jinfeng Luo, Yanmei Zhang, Jinxi Liao, Xiao-Chu Qin, Tingting Chen, Zhengchao Tu, John J. Talley
Publikováno v:
ACS Medicinal Chemistry Letters. 6:1086-1090
A series of novel anticancer agents were designed and synthesized based on coupling of different nonsteroidal anti-inflammatory drugs (NSAIDs) with the epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib. Both the antiprolife
Autor:
John J. Talley, Jingfang Xiong, He Chuang, Wang Yican, Zhengchao Tu, Micky D. Tortorella, Miaoqin She, Minke Li, Yanmei Zhang, Yongzhi Lu, Xiao-Chu Qin, Qiong Pan, Tingting Chen, Xiaorong Liu
Publikováno v:
Journal of medicinal chemistry. 60(10)
In this report, we disclose the design and synthesis of a series of pentafluorosulfanyl (SF5) benzopyran derivatives as novel COX-2 inhibitors with improved pharmacokinetic and pharmacodynamic properties. The pentafluorosulfanyl compounds showed both
Autor:
John J. Talley, Liu Jianqi, Dingsheng Wen, Lu Xin, Zhengchao Tu, Micky D. Tortorella, Yanmei Zhang, Xiaorong Liu, Wang Yican, Yang Bai, Yongzhi Lu
Publikováno v:
ACS Medicinal Chemistry Letters. 5:1162-1166
We designed a series of specifically deuterated benzopyran analogues as new COX-2 inhibitors with the aim of improving their pharmacokinetic properties. As expected, the deuterated compounds retained potency and selectivity for COX-2. The new molecul
Publikováno v:
The Open Organic Chemistry Journal. 7:15-20
Palladium catalysis is an efficient way to obtain trimethylsilyl substituted benzopyran derivatives. After screen- ing a series of reactions , we found optimized conditions.
Autor:
Ann E. Hallinan, Jeffery S. Carter, David G. Brown, John J. Talley, Timothy Maziasz, Karl W. Aston, Bruce C. Hamper, Matthew J. Graneto, Koszyk Francis, Jaime L. Masferrer, Ludwig Cindy L, Jane L. Wang, David C. Limburg
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:7164-7168
In this manuscript, we report the discovery of the substituted 2-trifluoromethyl-2H-benzopyran-3-carboxylic acids as a novel series of potent and selective cyclooxygenase-2 (COX-2) inhibitors. We provide the structure–activity relationships, optimi